Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 360-degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cardiovascular diseases
3.2.1.2 High investment in the research and development of drugs
3.2.1.3 Increase in elderly population
3.2.1.4 Growing awareness and screening programs
3.2.2 Industry pitfalls & challenges
3.2.2.1 Frequent product recalls/discontinuation
3.2.2.2 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutes
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategy outlook matrix
Chapter 5 Market Estimates and Forecast, By Drug Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Clofibrate
5.3 Gemfibrozil
5.4 Fenofibrate
5.5 Other drug types
Chapter 6 Market Estimates and Forecast, By Product Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Branded
6.3 Generic
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hypercholesterolemia
7.3 Heart attacks
7.4 Hypertriglyceridemia
7.5 Other indications
Chapter 8 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Oral
8.3 Injectable
Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Hospital pharmacy
9.3 Retail pharmacy
9.4 Online pharamcy
Chapter 10 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 Hospitals
10.3 Homecare settings
10.4 Specialty clinics
10.5 Other end-users
Chapter 11 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.5.4 Rest of Latin America
11.6 Middle East and Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 UAE
11.6.4 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Aurobindo Pharma Limited
12.2 Abbott Laboratories
12.3 Cipla Inc.
12.4 IOL Chemicals and Pharmaceuticals Limited
12.5 Lupin Limited
12.6 Mylan N.V.
12.7 Pfizer Inc.
12.8 Sanofi
12.9 Sun Pharmaceutical Industries Ltd.
12.10 Unnati Pharmaceuticals Pvt Ltd.
12.11 Zydus Lifesciences Limited
